Thera-SAbDab

ENLONSTOBART

>   Structural Summary
TherapeuticEnlonstobart
TargetPDCD1/CD279/PD1
Heavy ChainQVQLVESGGGVVQPGRSLRLTCKASGLTFSSSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNNDYWGQGTLVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYTASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYSNWPRTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv Structure5ggq [Fvs: HL], 5ggr [Fvs: AB, HL], 5wt9 [Fvs: HL]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Enlonstobart.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 97.27%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 101 102 103 104 105 106 107 108 109 110 111 112 113
enlonstobart Q V Q L V E S G G G V V Q P G R S L R L T C K A S G L T F S S S G M H W V R Q A P G K G L E W V A V I W Y D G S K R Y Y A D S V K G R F T I S R D N S K N T L F L Q M N S L R A E D T A V Y Y C A T N N D Y W G Q G T L V T V S S
5ggr Q V Q L V E S G G G V V Q P G R S L R L D C K A S G I T F S N S G M H W V R Q A P G K G L E W V A V I W Y D G S K R Y Y A D S V K G R F T I S R D N S K N T L F L Q M N S L R A E D T A V Y Y C A T N D D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
enlonstobart E I V L T Q S P A T L S L S P G E R A T L S C R A S Q S V S S Y L A W Y Q Q K P G Q A P R L L I Y T A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q Y S N W P R T F G Q G T K V E I K
5ggr E I V L T Q S P A T L S L S P G E R A T L S C R A S Q S V S S Y L A W Y Q Q K P G Q A P R L L I Y D A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q S S N W P R T F G Q G T K V E I K
Sequence identity: 97.27%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 101 102 103 104 105 106 107 108 109 110 111 112 113
enlonstobart Q V Q L V E S G G G V V Q P G R S L R L T C K A S G L T F S S S G M H W V R Q A P G K G L E W V A V I W Y D G S K R Y Y A D S V K G R F T I S R D N S K N T L F L Q M N S L R A E D T A V Y Y C A T N N D Y W G Q G T L V T V S S
5ggq Q V Q L V E S G G G V V Q P G R S L R L D C K A S G I T F S N S G M H W V R Q A P G K G L E W V A V I W Y D G S K R Y Y A D S V K G R F T I S R D N S K N T L F L Q M N S L R A E D T A V Y Y C A T N D D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
enlonstobart E I V L T Q S P A T L S L S P G E R A T L S C R A S Q S V S S Y L A W Y Q Q K P G Q A P R L L I Y T A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q Y S N W P R T F G Q G T K V E I K
5ggq E I V L T Q S P A T L S L S P G E R A T L S C R A S Q S V S S Y L A W Y Q Q K P G Q A P R L L I Y D A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q S S N W P R T F G Q G T K V E I K
Sequence identity: 97.27%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 101 102 103 104 105 106 107 108 109 110 111 112 113
enlonstobart Q V Q L V E S G G G V V Q P G R S L R L T C K A S G L T F S S S G M H W V R Q A P G K G L E W V A V I W Y D G S K R Y Y A D S V K G R F T I S R D N S K N T L F L Q M N S L R A E D T A V Y Y C A T N N D Y W G Q G T L V T V S S
5wt9 Q V Q L V E S G G G V V Q P G R S L R L D C K A S G I T F S N S G M H W V R Q A P G K G L E W V A V I W Y D G S K R Y Y A D S V K G R F T I S R D N S K N T L F L Q M N S L R A E D T A V Y Y C A T N D D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
enlonstobart E I V L T Q S P A T L S L S P G E R A T L S C R A S Q S V S S Y L A W Y Q Q K P G Q A P R L L I Y T A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q Y S N W P R T F G Q G T K V E I K
5wt9 E I V L T Q S P A T L S L S P G E R A T L S C R A S Q S V S S Y L A W Y Q Q K P G Q A P R L L I Y D A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q S S N W P R T F G Q G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (Aug '24)Phase-II
Estimated Status (Aug '24)Active
Recorded Developmental Technology
INN Year Proposed2023
INN Year RecommendedNone
Companies InvolvedHangzhou Sumgen Biotech, CSPC ZhongQi Pharmaceutical Technology, Hangzhou Sumgen Biotech
Conditions Approvedna
Conditions ActiveCervical cancer, Triple negative breast cancer
Conditions DiscontinuedLymphoma, Mesothelioma, Non-small cell lung cancer, Solid tumours
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy